InspireSemi completes Delaware redomicile while Definium Therapeutics issues employee inducement grants
InspireSemi finalized its redomicile to Delaware and Definium Therapeutics granted options covering 45,940 shares to two newly hired non‑executive staff.
By Felo News Desk · Published
InspireSemi announced that it completed the redomicile of its corporate domicile to the state of Delaware, and Definium Therapeutics disclosed the issuance of employee inducement grants covering 45,940 common shares to two newly hired non‑executive employees, both on Oct. 13, 2026.
What happened
According to the Financial Post, InspireSemi filed the necessary paperwork to move its legal domicile from its previous jurisdiction to Delaware, completing the process on Oct. 13, 2026. In a separate filing, Definium Therapeutics issued stock options to two newly hired non‑executive employees, with the options representing an aggregate of 45,940 common shares. The grant dates were effective on Oct. 13, 2026, and the options will vest over four years, with 25% vesting after the first year.
What the reports add
Financial Post’s coverage of InspireSemi’s redomicile notes that the move aligns the company with a jurisdiction commonly used by U.S. technology firms, though the article does not specify the prior domicile. The same outlet’s report on Definium Therapeutics adds that the exercise price of the options equals the closing price of Definium’s common shares on the grant date and that the vesting schedule follows a standard four‑year timeline.
What was said
The InspireSemi filing did not contain quoted remarks, and the Financial Post article provides no statements from company officials. Definium Therapeutics’ announcement likewise did not include direct quotations; the release simply described the terms of the inducement grants.
How it came about
InspireSemi’s redomicile follows a trend among technology‑focused companies to locate their legal base in Delaware, a state known for its flexible corporate statutes. Earlier this month, Felo News reported on AltaLink’s internal reorganization and onsemi’s revised merger terms, illustrating a broader pattern of corporate restructuring in the sector. Definium Therapeutics, a late‑stage clinical biopharma focused on psychiatric and neurological disorders, has previously announced its pipeline developments in Felo coverage, indicating ongoing efforts to attract talent through equity incentives.
Key facts
- InspireSemi completed the redomicile of its corporate domicile to Delaware on Oct. 13, 2026. (financialpost.com)
- Definium Therapeutics issued stock options covering 45,940 common shares to two newly hired non‑executive employees on Oct. 13, 2026. (financialpost.com)
- The Definium options vest over four years with 25% vesting after the first year. (financialpost.com)
